Business Description
![Edwards Lifesciences Corp Edwards Lifesciences Corp logo](https://static.gurufocus.com/logos/0C00000B3W.png?14)
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
ISIN : US28176E1082
Share Class Description:
EW: Ordinary SharesDescription
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.87 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.42 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 11.36 | |||||
Beneish M-Score | -1.85 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.4 | |||||
3-Year EBITDA Growth Rate | 20.6 | |||||
3-Year EPS without NRI Growth Rate | 11 | |||||
3-Year FCF Growth Rate | 0.3 | |||||
3-Year Book Growth Rate | 14.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 10.51 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.19 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 4.24 | |||||
9-Day RSI | 8.34 | |||||
14-Day RSI | 12.99 | |||||
6-1 Month Momentum % | 23.83 | |||||
12-1 Month Momentum % | -0.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.71 | |||||
Quick Ratio | 2.87 | |||||
Cash Ratio | 1.64 | |||||
Days Inventory | 286.7 | |||||
Days Sales Outstanding | 47.03 | |||||
Days Payable | 51.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.3 | |||||
Shareholder Yield % | 1.74 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 77.03 | |||||
Operating Margin % | 27.72 | |||||
Net Margin % | 24.55 | |||||
FCF Margin % | 4.19 | |||||
ROE % | 21.51 | |||||
ROA % | 15.48 | |||||
ROIC % | 21.37 | |||||
ROC (Joel Greenblatt) % | 53.1 | |||||
ROCE % | 18.6 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 25.67 | |||||
Forward PE Ratio | 22.99 | |||||
PE Ratio without NRI | 24.08 | |||||
Shiller PE Ratio | 34.46 | |||||
Price-to-Owner-Earnings | 301.32 | |||||
PEG Ratio | 1.37 | |||||
PS Ratio | 6.3 | |||||
PB Ratio | 5.05 | |||||
Price-to-Tangible-Book | 6.4 | |||||
Price-to-Free-Cash-Flow | 152.11 | |||||
Price-to-Operating-Cash-Flow | 72.04 | |||||
EV-to-EBIT | 22.38 | |||||
EV-to-Forward-EBIT | 18.58 | |||||
EV-to-EBITDA | 20.87 | |||||
EV-to-Forward-EBITDA | 16.58 | |||||
EV-to-Revenue | 5.78 | |||||
EV-to-Forward-Revenue | 5.28 | |||||
EV-to-FCF | 138.05 | |||||
Price-to-Projected-FCF | 2.12 | |||||
Price-to-DCF (Earnings Based) | 0.82 | |||||
Price-to-DCF (FCF Based) | 11.2 | |||||
Price-to-Median-PS-Value | 0.68 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.4 | |||||
Price-to-Graham-Number | 2.66 | |||||
Price-to-Net-Current-Asset-Value | 20.25 | |||||
Earnings Yield (Greenblatt) % | 4.47 | |||||
FCF Yield % | 0.67 | |||||
Forward Rate of Return (Yacktman) % | 19.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:EW
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edwards Lifesciences Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 5,999.1 | ||
EPS (TTM) ($) | 2.43 | ||
Beta | 1.03 | ||
Volatility % | 32.63 | ||
14-Day RSI | 12.99 | ||
14-Day ATR ($) | 3.807566 | ||
20-Day SMA ($) | 88.4905 | ||
12-1 Month Momentum % | -0.65 | ||
52-Week Range ($) | 58.93 - 96.12 | ||
Shares Outstanding (Mil) | 602.6 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Edwards Lifesciences Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Edwards Lifesciences Corp Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Edwards Lifesciences Corp Frequently Asked Questions
What is Edwards Lifesciences Corp(EW)'s stock price today?
The current price of EW is $62.37. The 52 week high of EW is $96.12 and 52 week low is $58.93.
When is next earnings date of Edwards Lifesciences Corp(EW)?
The next earnings date of Edwards Lifesciences Corp(EW) is 2024-10-25 Est..
Does Edwards Lifesciences Corp(EW) pay dividends? If so, how much?
Edwards Lifesciences Corp(EW) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |